Financial Report: Sanofi

Sanofi

3Q Revenues: €8.8 billion (+4%)

3Q Earnings: €1.9 billion (+8%)

YTD Revenues: €24.7 billion (+1%)

YTD Earnings: €5.0 billion (+3%)

Comments: Plavix sales were up 9% to €450 million in the quarter. Diabetes division sales were €1.8 billion, up 8%. Lantus sales increased 8% to €1.6 billion. Generics revenue increased 8% to €451 million reflecting the recovery in Brazil where sales were €76 million. Genzyme sales were up 25% to €649 million in the quarter driven by the growth of Aubagio and Fabrazyme. Sales grew 28% to €259 million in the U.S., 25% to €207 million in Western Europe, and 20% to €124 million in Emerging Markets. Sanofi Pasteur revenue increased 11% to €1.5 billion driven by strong performance of flu vaccines in the U.S. and in Emerging Markets as well as continued recovery of Pentacel and Adacel in the U.S.